Memantine Zentiva

Memantine, the active ingredient in Memantine Zentiva, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is prescribed for moderate to severe Alzheimer’s disease in adult patients, where it helps to mitigate excitotoxic neuronal injury and may modestly improve cognition and functional abilities.

GNH USA supplies Memantine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Memantine is an NMDA receptor antagonist used in the management of Alzheimer’s disease.

- Moderate Alzheimer’s disease: modest improvement in cognition and daily activities. - Severe Alzheimer’s disease: stabilization of functional decline and slower progression. - Alzheimer’s disease with behavioral disturbances: may help reduce agitation and improve overall patient comfort.

Memantine is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Dizziness: transient light‑headedness, especially at treatment initiation. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements, manageable with diet. - Confusion: occasional disorientation, more common in frail patients. - Hypertension: modest increase in blood pressure. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - Seizures: rare occurrence, requires immediate medical attention. - Severe skin rash or Stevens‑Johnson syndrome: urgent discontinuation needed. - Hepatic injury: elevated liver enzymes or hepatitis. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals. - Psychosis or hallucinations: new or worsening psychiatric symptoms. - Anaphylaxis: extremely rare allergic reaction.

Before initiating therapy, clinicians should consider several safety aspects.

- Renal impairment: dose may need adjustment; monitor renal function. - Hepatic impairment: use with caution; monitor liver enzymes. - History of seizures: assess risk and monitor closely. - Concomitant NMDA agonists: avoid co‑administration to prevent antagonistic effects. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Memantine may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Amantadine or other NMDA agonists: antagonistic effect reduces therapeutic benefit. - Strong renal tubular secretion inhibitors (e.g., cimetidine, trimethoprim): may increase memantine plasma levels. - Drugs that lower seizure threshold (e.g., bupropion, tramadol): heightened risk of seizures.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may blunt cognitive benefits. - Other Alzheimer’s drugs (e.g., donepezil, rivastigmine): monitor for additive side effects. - Diuretics (e.g., furosemide): watch for electrolyte disturbances. - NSAIDs: increased risk of hypertension. - Alcohol: may exacerbate dizziness and confusion.